Project Grant R43AI194889
Award Date 9/24/25
Completion Date 8/31/26
Dollars Obligated $306K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $597,542 Project Grant to Emory University under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to characterize the metabolic and epigenetic regulation of regulatory T cells (Tregs) in the skin, which play a key role in maintaining immune tolerance and suppressing autoimmunity. Using advanced single-cell metabolic profiling and genetic tools, the research...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $314,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Biotherapeutics, Inc., a clinical-stage biotechnology company in Blacksburg, Virginia. The funding will support the development of a novel oral small molecule therapeutic for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease affecting 1.5 million Americans. The company has identified a novel...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $769,366 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant, effective from February 1, 2025 to January 31, 2030, aims to decipher the ontogeny of CD4+ resident memory T cells that globally seed the skin and protect against cutaneous leishmaniasis. The...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the CFDA 93.855 Allergy and Infectious Diseases Research program, awarded a $300,000 Project Grant to Life Pharms Inc. on September 19, 2025. The grant supports the development of a novel antifungal drug, LP10581, to address the growing public health crisis of invasive, drug-resistant fungal infections. The project aims to further research and testing of this novel compound, which has shown promising in vitro and in vivo...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $807,799 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the University of Chicago. The grant, which runs from Jul 15, 2025 to Jun 30, 2030, supports research to investigate the role of a specialized subset of regulatory T cells in controlling self-reactive B cells and the production of autoantibodies. The research aims to identify these B cell-dependent...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $162,486 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Minnesota to investigate the local and systemic coordination of antiviral immunity by tissue-resident memory CD8 T cells in the skin. The project aims to determine whether CD8 TRM reactivation orchestrates immune cells in the skin and the extent to which skin TRM influence distal immunity....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $159,500 Project Grant on July 1, 2025 to the University of California, San Diego (UCSD) for the "Development of Novel Model to Measure TCR Signal Strength in Dual TCR Cells" project. This grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), will support UCSD's efforts to generate and validate a novel transgenic mouse model combining the B6.TCRA-AMCY reporter mouse with...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Electronic Biosciences, Inc. to develop a novel point-of-care technology for monitoring immunosuppressant drug levels. The key product being developed is a portable, fingerstick-based testing system that can provide convenient and frequent immunosuppressant drug level measurements. This will enable more precise dosing for...